3 Universities Join Cancer Testing Device Trial
Waco, TX-based Baylor University, Pennsylvania's University of Pittsburgh, and Ohio's University of Cincinnati have joined biopharmaceutical research and medical device company Chicago, IL-based CytoCore's current clinical trial of the e2 Collector, a medical device for detecting and treating reproductive-tract cancers.
CytoCore develops cancer screening systems used in laboratories or for point of care to assist in the early detection of cervical, endometrial, and other cancers. The three universities will join four other testing sites to help evaluate enhancements to the e2 Collector that speed testing and eliminate user errors in sampling.
"We are pleased to add these new sites to our on-going Collector Trial," said CytoCore's CEO Dr. Floyd Taub in a prepared statement. "This trial is expected to confirm and expand previous data on adequacy, sensitivity and specificity of CytoCore’s unique collector."
The study the schools are participating in is six times larger than a previous test reviewed by the FDA, according to Taub.
Read More:
About the Author
David Kopf is a freelance technology writer and marketing consultant, and can be reached at [email protected].
